

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3364396
<b>Application Number:</b>	10528344
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5049
<b>Title of Invention:</b>	Systems for expressing toxic proteins, vectors and method of producing toxic proteins
<b>First Named Inventor/Applicant Name:</b>	Pierre Falson
<b>Customer Number:</b>	21839
<b>Filer:</b>	Lisa E. Stahl/Lana Strawderman
<b>Filer Authorized By:</b>	Lisa E. Stahl
<b>Attorney Docket Number:</b>	034404-001
<b>Receipt Date:</b>	28-MAY-2008
<b>Filing Date:</b>	08-NOV-2005
<b>Time Stamp:</b>	09:52:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1050
RAM confirmation Number	15927
Deposit Account	024800
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	EOT.pdf	47812	no	1
			fca702985ac19aa4d817fbd1240b1d76e9050ef		

### Warnings:

### Information:

2		Amendment.pdf	771462	yes	13
			3019d3c630e966da0f8fde30c1cc737e93770f02		

### Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Amendment - After Non-Final Rejection	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	13

### Warnings:

### Information:

3	Specification	SubSpecClean.pdf	193715	no	42
			47b9af9821eb406c208a65f48b6dd8a10c51e5e9		

### Warnings:

### Information:

4	Specification	SubSpecMarked.pdf	199495	no	42
			aa69ca127f3509fe8e535f28fd5be02342918bdd		

### Warnings:

### Information:

5	Fee Worksheet (PTO-06)	fee-info.pdf	8196	no	2
			d79ee421ec2c5508bb0ea4f416b258cc3464ac70		

### Warnings:

### Information:

Total Files Size (in bytes):

1220680

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.